Attention A T users. To access the menus on this page please perform the following steps. 1. Please switch auto forms mode to off. 2. Hit enter to expand a main menu option (Health, Benefits, etc). 3. To enter and activate the submenu links, hit the down arrow. You will now be able to tab or arrow up or down through the submenu options to access/activate the submenu links.



Quick Links

Veterans Crisis Line Badge
My healthevet badge
EBenefits Badge

Updated Occupational PEP Guidelines, October 2013

for Health Care Providers

Updated Occupational PEP Guidelines

Updated guidelines for management of occupational exposures to HIV were published by the U.S. Public Health Service in September.

Among many important recommendations, the new guidelines:

  • Eliminate assessment of exposure severity as a means of determining the number of PEP drugs
  • Recommend PEP regimens consisting of at least 3 ARVs for all exposed persons
  • Recommend newer ARVs as "preferred" and "alternative" regimens for occupational PEP
    • Raltegravir + tenofovir DF/emtricitabine (Truvada) is the "preferred" HIV PEP regimen
  • Strongly emphasize the importance of ARV tolerability and convenience (eg, once-daily dosing, few pills) to enhance adherence
  • Strongly emphasize the importance of monitoring for adverse effects and otherwise supporting exposed persons to complete 28 days of PEP
  • Discuss the use of 4th-generation HIV Ag/Ab assays for follow-up testing: if these are used, testing can be concluded 4 months after exposure (as opposed to 6 months with other HIV antibody assays)
  • Recommend expert consultation for all HIV exposures

New guidelines for management of nonoccupational exposures are under consideration.